Efficacy of 3,4,3-LI(1,2-HOPO) for decorporation of Pu, Am and U from rats injected intramuscularly with high-fired particles of MOX.
This study aimed to assess the efficacy of 3,4,3-LI(1,2-HOPO) for reducing uranium, plutonium and americium in rats after intramuscular injection of (U-Pu)O2 particles (MOX). Sixteen rats were contaminated by intramuscular injection of a 1 mg MOX suspension and then treated daily for 7 d with LIHOPO (30 or 200 micromol kg(-1)) or DTPA (30 micromol kg(-1)). LIHOPO was inefficient for removing Pu, Am and U from the wound site. However, it reduced Pu retention in carcass and liver by factors of 2 and 6 respectively, and Am retention in carcass and liver by factors of 10 and 30. In contrast, the effect of LIHOPO on U was to decrease the retention in kidneys by a factor of 75. These results confirm that LIHOPO is a good candidate for use after contamination with MOX, in combination with localised wound lavage or surgical treatment aimed at removing most of the contaminant at the wound site.
Paquet
F
F
Institut de Radioprotection et de Sûreté Nucléaire, Département de Protection de la Santé de l'Homme et de Dosimétrie, Laboratoire d'Etudes Appliquées de Radiotoxicologie, Cedex, France. Francois.paquet@irsn.fr
Chazel
V
V
Houpert
P
P
Guilmette
R
R
Muggenburg
B
B
D000576:Americium / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000633:toxicity*; D000818:Animals; D001372:Aza Compounds / Q000008:administration & dosage*; D002614:Chelating Agents / Q000008:administration & dosage*; D015913:Chelation Therapy / Q000379:methods*; D003666:Decontamination / Q000379:methods; D005260:Female; D007273:Injections, Intramuscular; D009928:Organ Specificity; D010087:Oxides / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000633:toxicity; D011005:Plutonium / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000633:toxicity*; D011208:Powders; D011728:Pyridones / Q000008:administration & dosage*; D011832:Radiation Injuries / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D051381:Rats; D016896:Treatment Outcome; D017974:Uranium Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000633:toxicity*; D014915:Whole-Body Counting / Q000379:methods; D014950:Wounds, Penetrating / Q000150:complications / Q000188:drug therapy
D001372:Aza Compounds; D002614:Chelating Agents; D010087:Oxides; D011208:Powders; D011728:Pyridones; D017974:Uranium Compounds; C076998:N,N',N'',N'''-tetra(1,2-dihydro-1-hydroxy-2-oxopyridine-6-carbonyl)-1,5,10,14-tetraazatetradecane; D011005:Plutonium; C047385:uranium oxide; D000576:Americium